NASDAQ:ATXI Avenue Therapeutics (ATXI) Stock Price, News & Analysis $0.40 -0.13 (-24.76%) As of 07/25/2025 12:04 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Avenue Therapeutics Stock (NASDAQ:ATXI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avenue Therapeutics alerts:Sign Up Key Stats Today's Range$0.40▼$0.5150-Day Range$0.20▼$0.5352-Week Range$0.17▼$3.54Volume16,652 shsAverage Volume194,606 shsMarket Capitalization$1.26 millionP/E Ratio0.02Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Read More Avenue Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreATXI MarketRank™: Avenue Therapeutics scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Avenue Therapeutics. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Avenue Therapeutics is 0.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.97.Price to Earnings Ratio vs. SectorThe P/E ratio of Avenue Therapeutics is 0.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.10.Price to Book Value per Share RatioAvenue Therapeutics has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Avenue Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.48% of the float of Avenue Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvenue Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avenue Therapeutics has recently decreased by 2.72%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvenue Therapeutics does not currently pay a dividend.Dividend GrowthAvenue Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.99 Percentage of Shares Shorted2.48% of the float of Avenue Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvenue Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avenue Therapeutics has recently decreased by 2.72%, indicating that investor sentiment is improving. News and Social Media1.7 / 5News Sentiment0.07 News SentimentAvenue Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.06 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Avenue Therapeutics this week, compared to 3 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Avenue Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Avenue Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 17.34% of the stock of Avenue Therapeutics is held by institutions.Read more about Avenue Therapeutics' insider trading history. Receive ATXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATXI Stock News HeadlinesUniversity Avenue will be closed for repair due to a sinkhole in MorgantownJuly 20, 2025 | msn.com17-year-old dies from gunshot wound near Colley Avenue, police sayJuly 20, 2025 | msn.comTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trillions in oil, gas, lithium, and land rights. Whitney Tilson breaks it all down, and shows how everyday Americans can grab a stake. His urgent new briefing explains "The US: IPO"... and how to get in before the looming federal deadline.July 26 at 2:00 AM | Stansberry Research (Ad)Crash involving a fire engine reported on Tennessee Avenue in Bond HillJuly 20, 2025 | msn.comKatipunan Avenue now passable after billboard collapse forces temporary closureJuly 20, 2025 | msn.com"Dhaba on Devon Avenue" makes it to Writers Theatre in Glencoe, Illinois, after 5 yearsJuly 19, 2025 | msn.comEighteenth Avenue Family Enrichment Center joins program to provide free mealsJuly 19, 2025 | msn.comA section of Park Avenue is closing on Des Moines' south side as crews add sidewalksJuly 19, 2025 | msn.comSee More Headlines ATXI Stock Analysis - Frequently Asked Questions How have ATXI shares performed this year? Avenue Therapeutics' stock was trading at $2.00 at the beginning of the year. Since then, ATXI shares have decreased by 80.1% and is now trading at $0.3972. How were Avenue Therapeutics' earnings last quarter? Avenue Therapeutics, Inc. (NASDAQ:ATXI) posted its earnings results on Friday, August, 9th. The company reported ($6.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by $5.38. When did Avenue Therapeutics' stock split? Avenue Therapeutics shares reverse split on Friday, April 26th 2024.The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. When did Avenue Therapeutics IPO? Avenue Therapeutics (ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager. How do I buy shares of Avenue Therapeutics? Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avenue Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avenue Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), GE Aerospace (GE), CrowdStrike (CRWD) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings8/09/2024Today7/26/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ATXI CIK1644963 Webwww.avenuetx.com Phone(781) 652-4500FaxN/AEmployees4Year Founded2015Profitability EPS (Trailing Twelve Months)($7.49) Trailing P/E Ratio0.02 Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-471.57% Return on Assets-296.50% Debt Debt-to-Equity RatioN/A Current Ratio2.70 Quick Ratio2.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book0.21Miscellaneous Outstanding Shares3,183,000Free Float2,017,000Market Cap$1.26 million OptionableNot Optionable Beta-0.08 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:ATXI) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredElon Musk: “This will transform civilization as we know it.”Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.